Strategies for Gene Therapy in indications with low commercial viability

Time: 2:00 pm


  • The majority of neuromuscular diseases in MDA’s program affect less than 1000 people in the United States
  • To better address the needs of people with genetic NMDs that are not commercially viable MDA is launching an in-house biotech incubator to de-risk gene therapy programs for technologically feasible targets